Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.37)
# 367
Out of 5,116 analysts
146
Total ratings
53.79%
Success rate
17.31%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $14.25 | +952.63% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $8.23 | +203.77% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $103.37 | +93.48% | 1 | Nov 6, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $85 → $95 | $79.26 | +19.86% | 6 | Nov 5, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.19 | +1,269.86% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $75.80 | +45.12% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $104.10 | +29.69% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.69 | +271.75% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $72.13 | -9.88% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $39.84 | +88.25% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.87 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $28.62 | -12.65% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.48 | +129.89% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $12.85 | +94.55% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $6.68 | -10.18% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $208.98 | +33.98% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.65 | +266.30% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $4.18 | +378.47% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $252.17 | -14.74% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.32 | +115.52% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.65 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $11.38 | +163.62% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.97 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.45 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $47.96 | +87.66% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.76 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $177.88 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $70.16 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.16 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.11 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.71 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.69 | +2,081.50% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $44.84 | +44.96% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $9.26 | -46.00% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $3.48 | +216.09% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $145.26 | -10.51% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $784.97 | -3.18% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $26.87 | -44.18% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $10.37 | +430.38% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.84 | +1,530.43% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.20 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $14.16 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $598.91 | -58.26% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $100.11 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $79.93 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.08 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $24.81 | -11.33% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.84 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.95 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $229.98 | -58.69% | 1 | Aug 17, 2017 |
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $14.25
Upside: +952.63%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $8.23
Upside: +203.77%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $103.37
Upside: +93.48%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $85 → $95
Current: $79.26
Upside: +19.86%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.19
Upside: +1,269.86%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $75.80
Upside: +45.12%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $104.10
Upside: +29.69%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.69
Upside: +271.75%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $72.13
Upside: -9.88%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $39.84
Upside: +88.25%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.87
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $28.62
Upside: -12.65%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.48
Upside: +129.89%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $12.85
Upside: +94.55%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.68
Upside: -10.18%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $208.98
Upside: +33.98%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $13.65
Upside: +266.30%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $4.18
Upside: +378.47%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $252.17
Upside: -14.74%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.32
Upside: +115.52%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.65
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $11.38
Upside: +163.62%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.97
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $47.96
Upside: +87.66%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.76
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $177.88
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.16
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.11
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.71
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.69
Upside: +2,081.50%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $44.84
Upside: +44.96%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $9.26
Upside: -46.00%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $3.48
Upside: +216.09%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $145.26
Upside: -10.51%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $784.97
Upside: -3.18%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $26.87
Upside: -44.18%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $10.37
Upside: +430.38%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.84
Upside: +1,530.43%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.20
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $14.16
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $598.91
Upside: -58.26%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $100.11
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $79.93
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.08
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $24.81
Upside: -11.33%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $18.84
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $59.95
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $229.98
Upside: -58.69%